129 related articles for article (PubMed ID: 37165578)
1. FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways.
Dixit G; Gonzalez-Bosquet J; Skurski J; Devor EJ; Dickerson EB; Nothnick WB; Issuree PD; Leslie KK; Maretzky T
Clin Transl Med; 2023 May; 13(5):e1223. PubMed ID: 37165578
[TBL] [Abstract][Full Text] [Related]
2. Functional Distinctions of Endometrial Cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene.
Dixit G; Pappas BA; Bhardwaj G; Schanz W; Maretzky T
Cells; 2023 Sep; 12(18):. PubMed ID: 37759450
[TBL] [Abstract][Full Text] [Related]
3. Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17.
Maretzky T; Evers A; Zhou W; Swendeman SL; Wong PM; Rafii S; Reiss K; Blobel CP
Nat Commun; 2011; 2():229. PubMed ID: 21407195
[TBL] [Abstract][Full Text] [Related]
4. Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression.
Mori M; Mori T; Yamamoto A; Takagi S; Ueda M
Hum Cell; 2019 Jul; 32(3):367-378. PubMed ID: 30963412
[TBL] [Abstract][Full Text] [Related]
5. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
6. Drug-sensitive FGFR2 mutations in endometrial carcinoma.
Dutt A; Salvesen HB; Chen TH; Ramos AH; Onofrio RC; Hatton C; Nicoletti R; Winckler W; Grewal R; Hanna M; Wyhs N; Ziaugra L; Richter DJ; Trovik J; Engelsen IB; Stefansson IM; Fennell T; Cibulskis K; Zody MC; Akslen LA; Gabriel S; Wong KK; Sellers WR; Meyerson M; Greulich H
Proc Natl Acad Sci U S A; 2008 Jun; 105(25):8713-7. PubMed ID: 18552176
[TBL] [Abstract][Full Text] [Related]
7. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
Byron SA; Chen H; Wortmann A; Loch D; Gartside MG; Dehkhoda F; Blais SP; Neubert TA; Mohammadi M; Pollock PM
Neoplasia; 2013 Aug; 15(8):975-88. PubMed ID: 23908597
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.
Kim DH; Kwak Y; Kim ND; Sim T
Cancer Biol Ther; 2016; 17(1):65-78. PubMed ID: 26574622
[TBL] [Abstract][Full Text] [Related]
9. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
[TBL] [Abstract][Full Text] [Related]
10. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.
Ware KE; Marshall ME; Heasley LR; Marek L; Hinz TK; Hercule P; Helfrich BA; Doebele RC; Heasley LE
PLoS One; 2010 Nov; 5(11):e14117. PubMed ID: 21152424
[TBL] [Abstract][Full Text] [Related]
11. FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models.
Stehbens SJ; Ju RJ; Adams MN; Perry SR; Haass NK; Bryant DM; Pollock PM
J Cell Sci; 2018 Aug; 131(15):. PubMed ID: 30002137
[TBL] [Abstract][Full Text] [Related]
12. Members of the Fibroblast Growth Factor Receptor Superfamily Are Proteolytically Cleaved by Two Differently Activated Metalloproteases.
Dixit G; Schanz W; Pappas BA; Maretzky T
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804608
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.
Eritja N; Domingo M; Dosil MA; Mirantes C; Santacana M; Valls J; Llombart-Cussac A; Matias-Guiu X; Dolcet X
Mol Cancer Ther; 2014 Apr; 13(4):776-87. PubMed ID: 24448819
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.
Byron SA; Gartside MG; Wellens CL; Mallon MA; Keenan JB; Powell MA; Goodfellow PJ; Pollock PM
Cancer Res; 2008 Sep; 68(17):6902-7. PubMed ID: 18757403
[TBL] [Abstract][Full Text] [Related]
15. Utilization of unlabeled probes for the detection of fibroblast growth factor receptor 2 exons 7 and 12 mutations in endometrial carcinoma.
Liu T; Willmore-Payne C; Wallander ML; Layfield LJ
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):341-6. PubMed ID: 21285871
[TBL] [Abstract][Full Text] [Related]
16. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Jeske YW; Ali S; Byron SA; Gao F; Mannel RS; Ghebre RG; DiSilvestro PA; Lele SB; Pearl ML; Schmidt AP; Lankes HA; Ramirez NC; Rasty G; Powell M; Goodfellow PJ; Pollock PM
Gynecol Oncol; 2017 May; 145(2):366-373. PubMed ID: 28314589
[TBL] [Abstract][Full Text] [Related]
17. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
Kwak Y; Cho H; Hur W; Sim T
Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
[TBL] [Abstract][Full Text] [Related]
18. Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation.
Huang Y; Benaich N; Tape C; Kwok HF; Murphy G
Int J Biol Sci; 2014; 10(7):702-14. PubMed ID: 25013379
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
Byron SA; Loch DC; Pollock PM
Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
[TBL] [Abstract][Full Text] [Related]
20. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
Konecny GE; Finkler N; Garcia AA; Lorusso D; Lee PS; Rocconi RP; Fong PC; Squires M; Mishra K; Upalawanna A; Wang Y; Kristeleit R
Lancet Oncol; 2015 Jun; 16(6):686-94. PubMed ID: 25981814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
